NCT00002204View on ClinicalTrials.gov

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Conditions
HIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL

HIV p24/MF59 Vaccine

Trial Locations (1)

68178

Creighton Univ Med Ctr / Ped Infect Disease Div, Omaha

Sponsors

Lead Sponsor

Chiron Corporation
All Listed Sponsors
lead

Chiron Corporation

INDUSTRY